AI Article Synopsis
- Squamous cell carcinoma is less common in EGFR mutation-positive non-small cell lung cancers and responds poorly to early EGFR tyrosine kinase inhibitors compared to adenocarcinomas.
- A study highlighted a 57-year-old male with stage IIIC squamous cell lung cancer who had both an exon19 deletion and a T790M mutation identified through genetic testing.
- The patient was treated with osimertinib after other treatments failed, achieving a partial response that lasted over 20 months, suggesting that accurate genetic testing can help predict the effectiveness of EGFR-TKIs.
Article Abstract
Among epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancers, squamous cell carcinoma is less common and shows lower responsiveness to first-generation EGFR tyrosine kinase inhibitors (TKIs) compared to adenocarcinoma. However, the efficacy of osimertinib for squamous cell carcinoma with EGFR mutations is not well known. This study reports the case of a 57-year-old male diagnosed as having stage IIIC squamous cell lung cancer. Oncomine Dx Target Test identified EGFR exon19 deletion and de novo EGFR T790M mutation with variant allele frequencies (VAF) of 21.6% and 25.2%, respectively. The patient was treated with osimertinib after progression on chemoradiotherapy followed by durvalumab, and a partial response was maintained for more than 20 months. To predict EGFR-TKI efficacy, confirmation of gene mutations and VAF using next-generation sequencing is helpful.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10542461 | PMC |
| http://dx.doi.org/10.1111/1759-7714.15081 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!